{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:10:33Z","timestamp":1777662633141,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T00:00:00Z","timestamp":1231372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00259-008-0996-6","type":"journal-article","created":{"date-parts":[[2009,1,7]],"date-time":"2009-01-07T15:06:42Z","timestamp":1231340802000},"page":"484-498","source":"Crossref","is-referenced-by-count":19,"title":["Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?"],"prefix":"10.1007","volume":"36","author":[{"given":"Inga","family":"Buchmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf G.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Mier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,8]]},"reference":[{"key":"996_CR1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.leu.2404775","volume":"21","author":"N Kr\u00f6ger","year":"2007","unstructured":"Kr\u00f6ger N. Mini-Midi-Maxi? How to harness the graft-versus myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 2007;21:1851\u201358.","journal-title":"Leukemia"},{"key":"996_CR2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.10867","volume":"92","author":"D Blaise","year":"2007","unstructured":"Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukaemia. Haematologica 2007;92:533\u201341.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"996_CR3","first-page":"1995","volume":"46","author":"DA Mulford","year":"2005","unstructured":"Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted [alpha]-particle therapy. J Nucl Med 2005;46(Suppl 1):1995\u20132045.","journal-title":"J Nucl Med"},{"key":"996_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1040-8428(00)00132-3","volume":"38","author":"JG Jurcic","year":"2001","unstructured":"Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol 2001;38:37\u201345.","journal-title":"Crit Rev Oncol Hematol"},{"key":"996_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.beha.2006.10.003","volume":"20","author":"A Chaidos","year":"2007","unstructured":"Chaidos A, Kanfer E, Apperley JF. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol 2007;20:125\u201354.","journal-title":"Best Pract Res Clin Haematol"},{"key":"996_CR6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood 2008;111:1827\u201333.","journal-title":"Blood"},{"key":"996_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","volume":"107","author":"K Wheatley","year":"1999","unstructured":"Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council\u2019s Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69\u201379.","journal-title":"Br J Haematol"},{"key":"996_CR8","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752\u20139.","journal-title":"Blood"},{"key":"996_CR9","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","volume":"100","author":"C Preudhomme","year":"2002","unstructured":"Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717\u201323.","journal-title":"Blood"},{"key":"996_CR10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","volume":"76","author":"RA Clift","year":"1990","unstructured":"Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimen. Blood 1990;76:1867\u201371.","journal-title":"Blood"},{"key":"996_CR11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292\u2013302.","journal-title":"Blood"},{"key":"996_CR12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00277-003-0654-9","volume":"82","author":"N Kr\u00f6ger","year":"2003","unstructured":"Kr\u00f6ger N, Bornh\u00e4user M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine\/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003;82:336\u201342.","journal-title":"Ann Hematol"},{"key":"996_CR13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","volume":"108","author":"R Martino","year":"2006","unstructured":"Martino R, Iacobelli S, Brand R, et al.; Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836\u201346.","journal-title":"Blood"},{"key":"996_CR14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. N Engl J Med 1996;335:91\u20137.","journal-title":"N Engl J Med"},{"key":"996_CR15","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, et al.; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875\u201383.","journal-title":"N Engl J Med"},{"key":"996_CR16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929\u201336.","journal-title":"J Clin Oncol"},{"key":"996_CR17","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui W, Huff CA, Wang O, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332\u20136.","journal-title":"Blood"},{"key":"996_CR18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide regimen. N Engl J Med 1983;309:1347\u201353.","journal-title":"N Engl J Med"},{"key":"996_CR19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem cell transplantation. New Engl J 2006;354:1813\u201326.","journal-title":"New Engl J"},{"key":"996_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2005.09.001","volume":"43","author":"JL Ferrara","year":"2006","unstructured":"Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006;43:3\u201310.","journal-title":"Semin Hematol"},{"key":"996_CR21","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","volume":"8","author":"GR Hill","year":"1997","unstructured":"Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997;8:3204\u201313.","journal-title":"Blood"},{"key":"996_CR22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V86.3.890.890","volume":"86","author":"E Holler","year":"1995","unstructured":"Holler E, Kolb HJ, Mitterm\u00fcller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor \u03b1 (TNF\u03b1) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF\u03b1 (MAK 195F). Blood 1995;86:890\u20139.","journal-title":"Blood"},{"key":"996_CR23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1083-8791(03)70009-3","volume":"9","author":"JE Levine","year":"2003","unstructured":"Levine JE, Uberti JP, Ayash L, et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant 2003;9:189\u201397.","journal-title":"Biol Blood Marrow Transplant"},{"key":"996_CR24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/10428190109057983","volume":"41","author":"JM Boiron","year":"2001","unstructured":"Boiron JM, Lerner D, Pigneux A, et al. Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients. Leuk Lymphoma 2001;41:285\u201396.","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"996_CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF03165254","volume":"76","author":"A Newland","year":"2002","unstructured":"Newland A. Progress in the treatment of acute myeloid leukaemia in adults. Int J Hematol 2002;76(Suppl 1):253\u20138.","journal-title":"Int J Hematol"},{"key":"996_CR26","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2001.19.8.2134","volume":"19","author":"RP Witherspoon","year":"2001","unstructured":"Witherspoon RP, Deeg HJ, Storer B, et al. Haematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001;19:2134\u201341.","journal-title":"J Clin Oncol"},{"key":"996_CR27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","volume":"26","author":"D Valcarcel","year":"2008","unstructured":"Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukaemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577\u201384.","journal-title":"J Clin Oncol"},{"key":"996_CR28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V85.4.1122.bloodjournal8541122","volume":"85","author":"DC Matthews","year":"1995","unstructured":"Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplantation regimen for acute leukemia using targeted haematopoietic irradiation delivered by I-131-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995;85:1122\u201331.","journal-title":"Blood"},{"key":"996_CR29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/108497802753773775","volume":"17","author":"I Buchmann","year":"2002","unstructured":"Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-Antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation. Cancer Biother Radiopharm 2002;17:151\u201363.","journal-title":"Cancer Biother Radiopharm"},{"key":"996_CR30","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1158\/1078-0432.CCR-05-0211","volume":"11","author":"CM Richman","year":"2005","unstructured":"Richman CM, Denardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111\/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005;11:5920\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4 suppl","key":"996_CR31","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.10307","volume":"94","author":"TM Behr","year":"2002","unstructured":"Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94(4 suppl):1363\u201372.","journal-title":"Cancer"},{"key":"996_CR32","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","volume":"106","author":"A Nademanee","year":"2005","unstructured":"Nademanee A, Forman S, Molina A, et al. A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896\u2013902.","journal-title":"Blood"},{"key":"996_CR33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.V98.3.565","volume":"98","author":"D Bunjes","year":"2001","unstructured":"Bunjes D, Buchmann I, Duncker C, et al. Re-188-labeled anti-CD 66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: results of a phase I-II study. Blood 2001;98:565\u201372.","journal-title":"Blood"},{"key":"996_CR34","unstructured":"Loevinger R, Berman MA. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. Society of Nuclear Medicine, New York; 1976, MIRD Pamphlet No. 1."},{"key":"996_CR35","first-page":"882","volume":"35","author":"L Camera","year":"1994","unstructured":"Camera L, Kinuya S, Garmestani K, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 1994;35:882\u20139.","journal-title":"J Nucl Med"},{"key":"996_CR36","first-page":"278","volume":"47","author":"T Zenz","year":"2006","unstructured":"Zenz T, Schlenk RF, Glatting G, et al. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. J Nucl Med 2006;47:278\u201386.","journal-title":"J Nucl Med"},{"key":"996_CR37","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.surg.2006.07.030","volume":"140","author":"A Frilling","year":"2006","unstructured":"Frilling A, Weber F, Saner F, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006;140:968\u201376.","journal-title":"Surgery"},{"key":"996_CR38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12185-008-0044-0","volume":"87","author":"R Ratei","year":"2008","unstructured":"Ratei R, Karawajew L, Schabath R, et al. Differential expression of the carcinoembryonic antigen-related cell adhesion molecules panCD66, CD66a, CD66c and of sialyl-Lewis x (CD15s) on blast cells of acute leukemias. Int J Hematol 2008;87:137\u201343.","journal-title":"Int J Hematol"},{"key":"996_CR39","first-page":"440","volume":"3","author":"DA Scheinberg","year":"1989","unstructured":"Scheinberg DA, Tanimoto M, McKenzie S, et al. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 1989;3:440\u20135.","journal-title":"Leukemia"},{"key":"996_CR40","first-page":"6761","volume":"52","author":"PC Caron","year":"1992","unstructured":"Caron PC, Co MS, Bull MK, et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992;52:6761\u20137.","journal-title":"Cancer Res"},{"key":"996_CR41","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V83.7.1760.1760","volume":"83","author":"PC Caron","year":"1994","unstructured":"Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994;83:1760\u20138.","journal-title":"Blood"},{"key":"996_CR42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","volume":"94","author":"DC Matthews","year":"1999","unstructured":"Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237\u201347.","journal-title":"Blood"},{"key":"996_CR43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-002-1106-9","volume":"30","author":"I Buchmann","year":"2003","unstructured":"Buchmann I, Kull T, Glatting G, et al. A comparison of biodistribution and biokinetics of 99mTc-anti-CD66-mAb BW250\/183 and 99mTc-anti-CD45-mAb YTH24.5 with regard to suitability for myeloablative radioimmunotherapy. Eur J Nucl Med Mol Imaging 2003;30:667\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"996_CR44","first-page":"1335","volume":"47","author":"G Glatting","year":"2006","unstructured":"Glatting G, M\u00fcller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted radioimmunotherapy for acute leukemia. J Nucl Med 2006;47:1335\u201341.","journal-title":"J Nucl Med"},{"key":"996_CR45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1200\/JCO.1993.11.2.294","volume":"11","author":"MA Schwartz","year":"1993","unstructured":"Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993;11:294\u2013303.","journal-title":"J Clin Oncol"},{"key":"996_CR46","first-page":"372","volume":"6","author":"JG Jurcic","year":"2000","unstructured":"Jurcic JG, DeBlasio T, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000;6:372\u201380.","journal-title":"Clin Cancer Res"},{"key":"996_CR47","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/1042819021000033015","volume":"43","author":"D Bunjes","year":"2002","unstructured":"Bunjes D. Re-188-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2002;43:2125\u201331.","journal-title":"Leuk Lymphoma"},{"key":"996_CR48","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s002590100544","volume":"28","author":"SN Reske","year":"2001","unstructured":"Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med 2001;28:807\u201315.","journal-title":"Eur J Nucl Med"},{"key":"996_CR49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2141.2005.05663.x","volume":"130","author":"M Ringhoffer","year":"2005","unstructured":"Ringhoffer M, Blumstein N, Neumaier B, et al. 188Re or 90Y-labeled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol 2005;130:604\u201313.","journal-title":"Br J Haematol"},{"key":"996_CR50","doi-asserted-by":"crossref","unstructured":"Orchard KH, Cooper M, Lewington V, et al. Targeted radiotherapy in haematopoietic stem cell transplantation: results of a phase I trial using a yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistent BM targeting. Bone Marrow Transplant 2006;37(Suppl), p. 45, O338.","DOI":"10.1016\/j.bbmt.2005.11.036"},{"issue":"Suppl","key":"996_CR51","first-page":"5908s","volume":"55","author":"JG Jurcic","year":"1995","unstructured":"Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995;55(Suppl):5908s\u201310s.","journal-title":"Cancer Res"},{"key":"996_CR52","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","volume":"100","author":"JG Jurcic","year":"2002","unstructured":"Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233\u20139.","journal-title":"Blood"},{"issue":"Suppl","key":"996_CR53","first-page":"314P","volume":"43","author":"I Buchmann","year":"2002","unstructured":"Buchmann I, Mutschler J, Steinbach G, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb before stem cell transplantation does not increase cytokine levels (abstract). J Nucl Med 2002;43(Suppl):314P.","journal-title":"J Nucl Med"},{"issue":"Suppl","key":"996_CR54","first-page":"37P","volume":"43","author":"I Buchmann","year":"2002","unstructured":"Buchmann I, Schultz A, Sparber M, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-mAb in paediatric leukaemia patients: a phase I-trial. J Nucl Med 2002;43(Suppl):37P.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-008-0996-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-008-0996-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-008-0996-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T12:37:56Z","timestamp":1589459876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-008-0996-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,8]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1007\/s00259-008-0996-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,8]]}}}